CEO & Founder CUTTIS AG
Our Solution – Personalized, bio-engineered, dermo-epidermal skin grafts
After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.
Since 2016, CUTISS is supported by WYSS ZURICH, that finances the clinical trial programs and offers the manufacturing facility for DenovoSkin.